Figure 7. T-BET supports the fitness of MYD88-mutant B-cells.

A, Experimental scheme for B-D. ON = Overnight; A.T. = Adoptive transfer.

B, FC profiling of donor B-cell contribution to total GCB.

C, FC analysis of T-BET+ donor-derived GCB.

D, FC analysis of KI67 expression in donor-derived GCB.

E, FC analysis of donor B-cell contribution to AiBC-like MBC.

F, RNA-Seq-based TBX21 expression in primary specimens from (left) NCI (47) or (right) BCCA (48,49) cohorts.

G, uMAP depiction of single-cell RNA-Seq data from EBV/HBV-negative DLBCL tumors (50).

H, Relative expression of the ITGAX module among specimens in (G).

I, RNA-Seq-based TBX21 expression in primary human DLBCL specimens.

J, Representative images and quantification of T-BET IHC in specimens from the BCCA cohort (52). Scale = 20μm.

K, Experimental scheme for (L).

L, (Left) Penetrance of targeted genomic alterations, at time of cell plating. (Center) Number of detectable clonal outgrows 30 days after plating. (Right) WB-based T-BET expression in clonal outgrows. Representative blots for 2 clones per gRNA.

M, Schematic representation of the proposed transformation model.

Values represent mean ± SEM. P-values calculated using unpaired two-tailed Student’s t-test (B-F), or one-way ANOVA with Tukey’s post-test (I).